Exclusive Summary

• UB696 is a broad-potential, oral, once-daily (QD) small molecule SLC6A19 inhibitor with Best-in-Class potential for Phenylketonuria (PKU) and Chronic Kidney Disease (CKD).
• The MoA is highly differentiated and significantly de-risked, as the therapeutic target has already achieved global clinical proof-of-concept (POC) via a competitor's Phase 3 trial.
• Preclinical models demonstrate superior efficacy over the late-stage clinical benchmark (JNT517) in reducing plasma phenylalanine levels for PKU.
• When applied to CKD, UB696 shows a robust synergistic renal-protective effect when combined with SGLT-2 inhibitors, perfectly aligning with current mega-blockbuster combination treatment paradigms.
• It poses massive global out-licensing appeal by offering overseas partners a dual commercial strategy: premium pricing via the orphan PKU pathway and a multi-billion dollar mass-market play in CKD.

Asset Materials

Contact Us for Full Materials